Dr Reddy's teams with API firm TR-Pharma to launch biosimilars in Turkey

By Gareth Macdonald

- Last updated on GMT

Dr Reddy's preps to launch biosims in Turkey (picture iStock/dkaranouh)
Dr Reddy's preps to launch biosims in Turkey (picture iStock/dkaranouh)

Related tags Dr reddy Active ingredient Pharmaceutical drug

Dr Reddy’s Laboratories and TR-Pharma have partnered to manufacture biosimilar pharmaceuticals for the Turkish market.

The deal – announced in a Bombay Stock Exchange (BSE) filing​ – is focused on the registration and commercialization of three Dr Reddy’s biosimilar products in Turkey.

TR-Pharma will register the drugs – details of which have not been released – and will also produce the active pharmaceutical ingredients (APIs) for the three products.

The agreement will also see Dr Reddy’s transfer manufacturing technology and processes to Istanbul-headquartered TR-Pharm.

TR-Pharm general manager Mehmet Goker said: “Biosimilars are a key component of our investment strategy in Turkey to establish biotechnological API production for national use and regional exports.​”

Dr Reddy’s portfolio of biosimilar products includes versions of Aranesp (darbopoetin alfa), Neupogen (filgrastim) and Neulasta (pegfilgrastrim) and MabThera (rituximab).

Neither firm responded to a request for comment.

Biosimilars in Turkey

Russia’s CJSC Biocad agreed to supply Turkey’s Kocak Farma with the API for rituximab in a five-year supply and commercialisation deal signed in 2013​.

In 2015, Turgut Ilaç announced gained access to biosimilar manufacturing technology in an agreement with Merck Millipore. The deal also saw the latter provide Turgut with facility design services and process development support.

At the time Turgut Ilaç said the initial focus of the manufacturing collaboration will be biosimilars for the treatment of non-small cell lung carcinoma and rheumatoid arthritis.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more